Read more about:

Auctus Biologics

about ductus biologics

Monoclonal antibodies are a major class of therapeutics with a dozen or more being approved by the FDA every year. These treatments have huge annual revenues, with Humira (treating arthritis) grossing over $20B and Herceptin (treating HER2 breast cancer) grossing over $6B. 

The Auctus antibody mimetic platform has significant potential to reduce costs, allowing delivery to a much larger group of patients. Auctus is already in negotiation with some of the major pharmaceutical companies for sale and/or licencing of its technology


Contact us

Let's Get Rejuvenated!

We’re happy to answer any questions you may have and help you determine your best practices to learn and invest in rejuvenation.

For more information about:
Schedule a Consultation

Start your journey to rejuvenation

Quick Links